Trial reportJournal of pain and symptom management2010
Pilot trial of a patient-specific cutaneous electrostimulation device (MC5-A Calmare®) for chemotherapy-induced peripheral neuropathy.
Trial report in Journal of pain and symptom management, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03707444 (A Pilot Trial of Scrambler Therapy for Pain Associated With Pancreas Cancer), which is not on this map. Cited by 47 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Pilot Trial of Scrambler Therapy for Pain Associated With Pancreas Cancer
Who cites it
47 citing papers in PubMed, 2 syntheses or guidelines pooled it, 103 citations in OpenAlex.
- Research trends of acupuncture therapy for painful peripheral nervous system diseases from 2004 to 2023: a bibliometric and meta-analysis.Frontiers in neurology · 2025Pooled it
- Evidence-Based Treatment of Pain in Chemotherapy-Induced Peripheral Neuropathy.Current pain and headache reports · 2023Pooled it
- Scrambler therapy for treatment of poststroke pain.Annals of clinical and translational neurology · 2024Trial
- Differential response to scrambler therapy by neuropathic pain phenotypes.Scientific reports · 2021Trial
- Scrambler therapy improves pain in neuromyelitis optica: A randomized controlled trial.Neurology · 2020Trial
- Scrambler therapy for chemotherapy neuropathy: a randomized phase II pilot trial.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2020Trial
- Wireless transcutaneous electrical nerve stimulation device for chemotherapy-induced peripheral neuropathy: an open-label feasibility study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2019Trial
- Magnetic field therapy in patients with cytostatics-induced polyneuropathy: A prospective randomized placebo-controlled phase-III study.Bioelectromagnetics · 2017Trial
- Evaluation of the treatment of chronic chemotherapy-induced peripheral neuropathy using long-wave diathermy and interferential currents: a randomized controlled trial.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2016Trial
- Pilot evaluation of Scrambler therapy for the treatment of chemotherapy-induced peripheral neuropathy.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2015Trial
- A trial of Scrambler therapy in the treatment of cancer pain syndromes and chronic chemotherapy-induced peripheral neuropathy.Journal of pain & palliative care pharmacotherapy · 2013Trial
- Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2013Trial
- Review
- Randomized Controlled Trial to Relieve Pain of Chemotherapy-Induced Peripheral Neuropathy by Magnetic Field: SMILE Study.Cancers · 2026Article
- Precision acupuncture for chemotherapy-induced peripheral neuropathy: multitarget mechanisms and integrated clinical translation framework.Frontiers in neurology · 2026Review
- Chemotherapy-induced peripheral neuropathy in patients with breast cancer treated with taxanes (Review).Oncology letters · 2025Review
- The treatment of chemotherapy-induced peripheral neuropathy: a review of current management options and a potential role for scrambler therapy.Frontiers in pain research (Lausanne, Switzerland) · 2025Review
- Treatment and diagnosis of chemotherapy-induced peripheral neuropathy: An update.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022Review
- Cerebral current-source distribution associated with pain improvement by non-invasive painless signaling therapy in patients with failed back surgery syndrome.The Korean journal of pain · 2021Article
- Chemotherapy-induced neurotoxicity in the treatment of gynecological cancers: State of art and an innovative approach for prevention.World journal of clinical oncology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
contextChemotherapy-induced peripheral neuropathy (CIPN) is a major dose-limiting and persistent consequence of numerous classes of antineoplastic agents, affecting up to 30%-40% of patients. To date, there is no effective prevention or therapy. An evolving hypothesis for reducing CIPN pain involves direct nerve stimulation to reduce the pain impulse.
objectivesTo evaluate the impact on CIPN associated with the MC5-A Calmare® therapy device.
methodsThe MC5-A Calmare® therapy device is designed to generate a patient-specific cutaneous electrostimulation to reduce the abnormal pain intensity. Sixteen patients from one center received one-hour interventions daily over 10 working days.
resultsOf 18 patients, 16 were evaluable. The mean age of the patients was 58.6 years-four men and 14 women-and the duration of CIPN was three months to eight years. The most common drugs were taxanes, platinums, and bortezomib (Velcade, Millenium Pharmaceuticals, Cambridge MA). At the end of the study (Day 10), a 20% reduction in numeric pain scores was achieved in 15 of 16 patients. The pain score fell 59% from 5.81±1.11 before treatment to 2.38±1.82 at the end of 10 days (P<0.0001 by paired t-test). A daily treatment benefit was seen with a strong statistically significant difference between the pre- and post-daily pain scores (P<0.001). Four patients had their CIPN reduced to zero. A repeated-measures analysis using the scores from all 10 days confirmed these results. No toxicity was seen. Some responses have been durable without maintenance.
conclusionPatient-specific cutaneous electrostimulation with the MC5-A Calmare® device appears to dramatically reduce pain in refractory CIPN patients with no toxicity. Further studies are underway to define the benefit, mechanisms of action, and optimal schedule.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.